Literature DB >> 19062323

Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?

C E M Hollak1, G E Linthorst.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19062323     DOI： 10.1016/j.ymgme.2008.10.013

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN： 1096-7192            Impact factor:   4.797


× No keyword cloud information.
  13 in total

1.  Unravelling the mechanism of action of enzyme replacement therapy in Fabry disease.

Authors:  Younhee Ko; CheolHo Lee; Myeong Hee Moon; Geu-Ru Hong; Chong-Kun Cheon; Jin-Sung Lee
Journal:  J Hum Genet       Date:  2015-10-22       Impact factor: 3.172

2.  Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease.

Authors:  Malte Lenders; Jörg Stypmann; Thomas Duning; Boris Schmitz; Stefan-Martin Brand; Eva Brand
Journal:  J Am Soc Nephrol       Date:  2015-04-30       Impact factor: 10.121

Review 3.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

Review 4.  Emptying the stores: lysosomal diseases and therapeutic strategies.

Authors:  Frances M Platt
Journal:  Nat Rev Drug Discov       Date:  2017-11-17       Impact factor: 84.694

Review 5.  Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.

Authors:  Kenneth J Valenzano; Richie Khanna; Allan C Powe; Robert Boyd; Gary Lee; John J Flanagan; Elfrida R Benjamin
Journal:  Assay Drug Dev Technol       Date:  2011-06       Impact factor: 1.738

Review 6.  Enzyme replacement therapy for Anderson-Fabry disease.

Authors:  Regina El Dib; Huda Gomaa; Raíssa Pierri Carvalho; Samira E Camargo; Rodrigo Bazan; Pasqual Barretti; Fellype C Barreto
Journal:  Cochrane Database Syst Rev       Date:  2016-07-25

Review 7.  Pre-existing Antibody: Biotherapeutic Modality-Based Review.

Authors:  Boris Gorovits; Adrienne Clements-Egan; Mary Birchler; Meina Liang; Heather Myler; Kun Peng; Shobha Purushothama; Manoj Rajadhyaksha; Laura Salazar-Fontana; Crystal Sung; Li Xue
Journal:  AAPS J       Date:  2016-01-28       Impact factor: 4.009

8.  The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease.

Authors:  Suhrad G Banugaria; Sean N Prater; Yiu-Ki Ng; Joyce A Kobori; Richard S Finkel; Roger L Ladda; Yuan-Tsong Chen; Amy S Rosenberg; Priya S Kishnani
Journal:  Genet Med       Date:  2011-08       Impact factor: 8.822

9.  Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy.

Authors:  Juna M de Vries; Esther Kuperus; Marianne Hoogeveen-Westerveld; Marian A Kroos; Stephan C A Wens; Merel Stok; Nadine A M E van der Beek; Michelle E Kruijshaar; Dimitris Rizopoulos; Pieter A van Doorn; Ans T van der Ploeg; W W M Pim Pijnappel
Journal:  Genet Med       Date:  2016-06-30       Impact factor: 8.822

10.  Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease.

Authors:  Suhrad G Banugaria; Sean N Prater; Judeth K McGann; Jonathan D Feldman; Jesse A Tannenbaum; Carrie Bailey; Renuka Gera; Robert L Conway; David Viskochil; Joyce A Kobori; Amy S Rosenberg; Priya S Kishnani
Journal:  Genet Med       Date:  2012-10-11       Impact factor: 8.822
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.